MedTrace Logo

Management of Ovarian Hyperstimulation Syndrome as a State of Defective Mineralocorticoid Response

NCT04351126 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 107

Last updated 2020-04-17

No results posted yet for this study

Summary

lines of evidence that support nature of ovarian hyperstimulation syndrome (OHSS) as "defective mineralocorticoid response" are cited, our hypothesis is tested clinically in both prophylaxis against and treatment of OHSS.

Conditions

  • Ovarian Hyperstimulation Syndrome

Interventions

DRUG

Fludrocortisone 0.1 Milligrams (mg)

0.2-0.6 mg/day of fludrocortisone is prescribed

DRUG

Bromocriptine

2.5 mg prescribed Vaginally twice daily

Sponsors & Collaborators

  • Ganin Fertility Center

    lead OTHER

Principal Investigators

  • Muhammad S Zeafan, MBBCH · Ganin Fertility Center

  • khaled M Elqusi, BSc · Ganin Fertility Center

  • Hossam Elattar, MBBCH · Ganin Fertility Center

  • Hosam Zaki, MSc, FRCOG · Ganin Fertility Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2020-02-25
Completion
2020-02-29

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04351126 on ClinicalTrials.gov